← Back to all trials
Active Not Recruiting
NCT05662488
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
Conditions: Hepatocellular Carcinoma, Bile Duct Cancer
Sex: All
Ages: 18 Years – 85 Years
Enrollment: 25
Sponsor: Peking Union Medical College Hospital
Location: China
Summary
The purpose of this study is to explore the ability of positron emission tomography (PET) with [68Ga]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with anti-PD-1 antibodies-based combination therapy.
Eligibility Criteria
Inclusion Criteria:locally advanced or metastatic and/or unresectable HCC or BTCChild Pugh A or B liver function statusan ECOG performance status score of 0-2Exclusion Criteria:intolerance to anti-PD-1-based combination therapyactive or prior autoimmune diseaseconcurrent use of immunosuppressive medicaments
Source: ClinicalTrials.gov (NCT05662488). StuddyBuddy aggregates publicly available trial information.
